CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Cigna (CI – Research Report), with a price target of ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Cigna and Centene were among a dozen companies that appeared on the initial JPM agenda that have bowed out of the conference.
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $7,625.07 today based on a ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Cigna Healthcare, the health benefits division of The Cigna Group (NYSE: CI), today announced a new offering in collaboration with Progyny, Inc (Nasdaq: PGNY) that makes best-in-class fertility ...